Related Experiment Video
Updated: Feb 13, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast
Gaochen Lan1, Jie Li2, Qiaomei Wen3
1Department of Oncology, Fujian Tingzhou Hospital, Longyan, Fujian 366300, P.R. China.
Abstract:
Cytotoxic T lymphocyte associated antigen 4 (CTLA-4) serves an important role in inhibiting anti-tumor immune response in the majority of solid tumors. However, a limited number of studies reported the function of CTLA-4 in luminal B HER2-negative breast cancer. Immunohistochemistry was performed to evaluate the expression of tumor and interstitial CTLA-4 in luminal B HER2-negative breast cancer tissues. The percentage of patients with tumor and interstitial CTLA-4+ was 41.2% (42/102) and 46.1% (47/102), respectively. There was a positive association between tumor CTLA-4 expression and interstitial CTLA-4 expression (P<0.05). The disease-free survival (DFS) of the tumor CTLA-4+ group was significantly shorter compared with patients with tumor CTLA-4- (mean, 89.070 vs. 39.022 months; P<0.0001). Additionally, the DFS of interstitial CTLA-4+ group was shorter compared with the interstitial CTLA-4- group (mean, 85.526 vs. 46.574 months; P<0.0001). Tumor and interstitial CTLA-4 expression may have prognostic predicting value in luminal B HER2-negative breast cancer. The present study may provide the basis for the use of a CTLA-4 blocker in patients with luminal B HER2-negative breast cancer.
Insights
Cytotoxic T lymphocyte associated antigen 4 (CTLA-4) expression in tumor and interstitial cells is linked to poorer outcomes in luminal B HER2-negative breast cancer. This suggests CTLA-4 blockers may benefit these patients.
Area of Science:
- Immunology
- Oncology
- Pathology
Background:
- Cytotoxic T lymphocyte associated antigen 4 (CTLA-4) is a key immune checkpoint inhibitor.
- Its role in luminal B HER2-negative breast cancer remains under-investigated.
- Understanding CTLA-4's function is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the expression of CTLA-4 in tumor and interstitial cells in luminal B HER2-negative breast cancer.
- To determine the prognostic significance of CTLA-4 expression on disease-free survival (DFS).
- To explore the potential of CTLA-4 blockade as a therapeutic strategy.
Main Methods:
- Immunohistochemistry was used to assess tumor and interstitial CTLA-4 expression in 102 patients.
- Statistical analysis was performed to correlate CTLA-4 expression with DFS.
- Kaplan-Meier survival analysis was employed to compare DFS between groups.
Main Results:
- CTLA-4 was expressed in 41.2% of tumors and 46.1% of interstitial spaces.
- A positive association was found between tumor and interstitial CTLA-4 expression.
- Both tumor and interstitial CTLA-4 positivity were significantly associated with shorter DFS (P<0.0001).
Conclusions:
- Tumor and interstitial CTLA-4 expression are significant negative prognostic factors in luminal B HER2-negative breast cancer.
- These findings support the potential utility of CTLA-4 inhibitors for this patient population.
- Further research is warranted to validate CTLA-4 as a therapeutic target.
Related Concept Videos
Predicting Molecular Geometry
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Negative Regulator Molecules
Prediction Intervals
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y.
Positive, Negative, and Zero Work
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...

